Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A collaboration between MORU and DNDi is ongoing to provide pharmacokinetic and pharmacodynamic modelling support to inform the development of novel drugs for neglected tropical diseases (e.g. leishmaniasis, Chagas disease and filariasis). The initial focus will be on filariasis with the aim to provide a rational modelling framework for in-vitro to in-vivo scaling, animal to human scaling, healthy volunteer to patient scaling, and to perform phase I-IV clinical trial evaluation of novel drugs under development.